Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesFree Cash FlowNet Cash FlowNet IncomeOther Working Capital Changes
Growth Metrics
Income Statement
Others
Ratios

Regen BioPharma (RGBPP) Free Cash Flow (2016 - 2025)

Historic Free Cash Flow for Regen BioPharma (RGBPP) over the last 12 years, with Q4 2025 value amounting to -$197941.0.

  • Regen BioPharma's Free Cash Flow fell 19819.82% to -$197941.0 in Q4 2025 from the same period last year, while for Dec 2025 it was -$515153.0, marking a year-over-year increase of 2142.01%. This contributed to the annual value of -$383591.0 for FY2025, which is 4895.91% up from last year.
  • Latest data reveals that Regen BioPharma reported Free Cash Flow of -$197941.0 as of Q4 2025, which was down 19819.82% from -$160005.0 recorded in Q3 2025.
  • Regen BioPharma's 5-year Free Cash Flow high stood at -$10463.0 for Q4 2022, and its period low was -$1.1 million during Q3 2021.
  • For the 5-year period, Regen BioPharma's Free Cash Flow averaged around -$170781.3, with its median value being -$118818.0 (2022).
  • Per our database at Business Quant, Regen BioPharma's Free Cash Flow skyrocketed by 9625.16% in 2022 and then plummeted by 145152.44% in 2023.
  • Regen BioPharma's Free Cash Flow (Quarter) stood at -$279135.0 in 2021, then surged by 96.25% to -$10463.0 in 2022, then plummeted by 1451.52% to -$162336.0 in 2023, then surged by 59.11% to -$66379.0 in 2024, then tumbled by 198.2% to -$197941.0 in 2025.
  • Its last three reported values are -$197941.0 in Q4 2025, -$160005.0 for Q3 2025, and -$55977.0 during Q2 2025.